Showing results (101-110 of 157) with videos related to
Sort By:
Pageof 16
Inflammatory Bowel Diseases|August 22, 2025
Systematic Review With Meta-Analysis: Safety and Effectiveness of Combining Biologics and Small Molecules in Inflammatory Bowel DiseasesScott R Anderson, Ali Osman, Mohammad Zamani, et al.Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|September 5, 2006
Phase I/II study of the mammalian target of rapamycin inhibitor everolimus (RAD001) in patients with relapsed or refractory hematologic malignanciesKaren W L Yee, Zhihong Zeng, Marina Konopleva, et al.Leukemia Research|May 27, 2005
Flavopiridol administered as a 24-hour continuous infusion in chronic lymphocytic leukemia lacks clinical activityIan W Flinn, John C Byrd, Nancy Bartlett, et al.Clinical Lymphoma, Myeloma & Leukemia|February 4, 2016
Patient Characteristics and Outcomes in Adolescents and Young Adults (AYA) With Acute Myeloid Leukemia (AML)Naveen Pemmaraju, Hagop Kantarjian, Farhad Ravandi, et al.Blood|August 9, 2011
Phase 2 study of cladribine followed by rituximab in patients with hairy cell leukemiaFarhad Ravandi, Susan O'Brien, Jeffrey Jorgensen, et al.Blood|June 17, 2004
Long-term survival benefit and improved complete cytogenetic and molecular response rates with imatinib mesylate in Philadelphia chromosome-positive chronic-phase chronic myeloid leukemia after failure of interferon-alphaHagop M Kantarjian, Jorge E Cortes, Susan O'Brien, et al.British Journal of Haematology|June 27, 2007
Biphenotypic acute leukaemia: a case seriesAhmed Aribi, Carlos Bueso-Ramos, Eli Estey, et al.Blood|October 24, 2002
Imatinib mesylate therapy in newly diagnosed patients with Philadelphia chromosome-positive chronic myelogenous leukemia: high incidence of early complete and major cytogenetic responsesHagop M Kantarjian, Jorge E Cortes, Susan O'Brien, et al.Cancer|August 27, 2004
Free circulating soluble CD52 as a tumor marker in chronic lymphocytic leukemia and its implication in therapy with anti-CD52 antibodiesMaher Albitar, Kim-Anh Do, Marcella M Johnson, et al.Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|February 25, 2005
Phase I study of BMS-214662, a farnesyl transferase inhibitor in patients with acute leukemias and high-risk myelodysplastic syndromesJorge Cortes, Stefan Faderl, Elihu Estey, et al.Pageof 16